secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0000899923-24-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics prelim Q4 revenue $196-197M; GAAP EPS loss ($0.35)-($0.36); adjusted EPS $0.02-0.03
--------------------------------------------------------------------------------

- Preliminary Q4 2023 revenue $196-197M; GAAP diluted EPS loss ($0.35)-($0.36); adjusted EPS $0.02-$0.03.
- FY2023 revenue growth reaffirmed at least 10% YoY; prenatal volume growth at least 10% in Q4.
- Reaffirmed positive adjusted operating cash flow in Q4 2023; guided estimated cash and credit at year-end.
- Excluded items for non-GAAP: stock-based comp ~$10.3M, amortization ~$10.7M, transformation costs ~$14.1M, legal ~$0.6M, tax ~$2.0M.
- Reaffirmed FY2023 revenue and non-GAAP guidance originally provided on Nov 6, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000005/0000899923-24-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992324000005/mygn-20240110.htm
  HTML page:      https://secwatch.observer/filing/0000899923-24-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer